-
公开(公告)号：KR101507358B1
公开(公告)日：2015-04-08
申请号：KR1020120120159
申请日：2012-10-29
Applicant: 대진대학교 산학협력단 , 충남대학교산학협력단
IPC: C12N15/53 , C12N15/63 , C12N9/02 , A61K31/711
Abstract: 본발명은세포의밀착이음강화방법에관한것이다. 이는 NADPH 퀴논옥시도리덕타제-1(NQO1, NADPH-quinone-oxidoreductase-1) 유전자또는그로부터발현되는단백질을목적분자로하여그 기능을강화하거나또는유전자발현율을높이는것으로이루어질수 있다. 구체적으로인간이나포유동물의대장의상피세포의염증반응이악화되는것은세포장벽기능이관련되어있으며, 또한세포장벽기능을 NQO1 유전자가조절한다는것에기초하여, 본발명은대장의상피세포의장벽기능소실로부터발생할수 있는염증반응의악화를억제함으로써각종급만성장염질환을효과적으로치료할수 있는치료법을제공할수 있다.
-
公开(公告)号：KR1020140056517A
公开(公告)日：2014-05-12
申请号：KR1020120120159
申请日：2012-10-29
Applicant: 대진대학교 산학협력단 , 충남대학교산학협력단
IPC: C12N15/53 , C12N15/63 , C12N9/02 , A61K31/711
Abstract: The present invention relates to a method for reinforcing a barrier function of a cell, by reinforcing the function or increasing gene expression by having an NADPH-quinone-oxidoreductase-1 (NQO1) gene or a protein expressed therefrom, as a target molecule. More specifically, the present invention is based on a cell barrier function relating to worsening of an inflammation of a large intestine epithelial cell of a human or a mammal, and an NQO1 gene adjusting the cell barrier function, to suppress the worsening of the inflammation caused by a loss of the barrier function of the large intestine epithelial cell and provide a treatment for effectively treating various acute and chronic enteritis diseases.
Abstract translation: 本发明涉及通过使NADPH-醌 - 氧化还原酶-1（NQO1）基因或其表达的蛋白质作为靶分子来增强功能或增加基因表达来增强细胞的屏障功能的方法。 更具体地，本发明是基于与人或哺乳动物的大肠上皮细胞的炎症恶化有关的细胞屏障功能和调节细胞屏障功能的NQO1基因，以抑制炎症恶化 通过损失大肠上皮细胞的屏障功能，并提供有效治疗各种急性和慢性肠炎疾病的治疗方法。
-
Patent Agency Ranking
公开(公告)号：KR1020130057012A
公开(公告)日：2013-05-31
申请号：KR1020110122713
申请日：2011-11-23
Applicant: 대진대학교 산학협력단
CPC classification number: A61K38/1767 , C07K14/43563 , Y10S424/81 , Y10S514/824 , Y10S514/825
Abstract: PURPOSE: A composition for suppressing immunocytes containing a coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient is provided to significantly suppress activation of macrophage without side effects such as cytotoxicity, and to develop a novel therapeutic agent for treating immune diseases including arteriosclerosis and rheumatoid arthritis. CONSTITUTION: A composition for suppressing immunocytes contains a coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient. The derivative is a regulator which suppresses activation of immunocytes. The immunocytes are macrophage. The derivative is D-type and is derived from an insect. The derivative is used for treating immune diseases including arteriosclerosis and rheumatoid arthritis.
Abstract translation: 目的：提供用于抑制作为活性成分的CopA3（9-聚体二硫化物二聚体）的Copris3（9-聚体二硫化物二聚体）作为活性成分的抑制免疫细胞的组合物，以显着抑制巨噬细胞的活化而无副作用，例如细胞毒性，并开发新的治疗剂 免疫疾病，包括动脉硬化和类风湿性关节炎。 构成：用于抑制免疫细胞的组合物含有共感染肽衍生物CopA3（9-聚体二硫化物二聚体）作为活性成分。 该衍生物是抑制免疫细胞活化的调节剂。 免疫细胞是巨噬细胞。 衍生物是D型，衍生自昆虫。 该衍生物用于治疗包括动脉硬化和类风湿性关节炎在内的免疫疾病。
-
公开(公告)号：KR101021226B1
公开(公告)日：2011-03-11
申请号：KR1020100037204
申请日：2010-04-22
Applicant: 대한민국(농촌진흥청장) , 대진대학교 산학협력단
CPC classification number: A61K38/08
Abstract: PURPOSE: A composition containing coprisin peptide derivative CopA3(HL) for treating Pseudomembranous colitis is provided to prevent antibiotics effect to helpful microbes such as Bifidobacterium and Lactobacillus. CONSTITUTION: A composition for treating Pseudomembranous colitis contains coprisin peptide derivative CopA3(HL) as an active ingredient. The coprisin peptide derivative CopA3(HL) has an amino acid sequence(L-L-C-I-A-L-R-K-K). The coprisin peptide derivative suppresses Clostrdium difficile in the large intestine. The coprisin peptide derivative CopA3(HL) is D-type.
Abstract translation: 目的：提供含有用于治疗假膜性结肠炎的复合蛋白肽衍生物CopA3（HL）的组合物，以防止抗生素对有益微生物如双歧杆菌和乳杆菌的作用。 构成：用于治疗假膜性结肠炎的组合物含有作为活性成分的共感染肽衍生物CopA3（HL）。 共聚蛋白肽衍生物CopA3（HL）具有氨基酸序列（L-L-C-I-A-L-R-K-K）。 共感染肽衍生物抑制大肠中的艰难梭菌（Clostrdium difficile）。 共聚蛋白肽衍生物CopA3（HL）是D型。
-
公开(公告)号：KR101336023B1
公开(公告)日：2013-12-03
申请号：KR1020110122714
申请日：2011-11-23
Applicant: 대진대학교 산학협력단
IPC: C12N5/0793 , C12N1/38 , C07K7/06
Abstract: 본 발명은 신경세포 성장 조절용 조성물에 관한 것이다. 이는 하기 아미노산 배열을 가지는 코프리신 펩티드 유도체 CopA3(9-mer disulfide dimer)를 유효 성분으로 함유할 수 있다.
본 발명의 조성물에 따르면, 예컨대 알츠하이머 증후군 또는 파킨슨 증후군과 같은 퇴행성 신경질환의 치료제로서 비용이 저렴하면서도 부작용이 없는 새로운 치료제의 제공이 가능하다는 등의 현저한 효과가 있다.-
公开(公告)号：KR1020130057013A
公开(公告)日：2013-05-31
申请号：KR1020110122714
申请日：2011-11-23
Applicant: 대진대학교 산학협력단
IPC: C12N5/0793 , C12N1/38 , C07K7/06
CPC classification number: C12N5/0619 , C07K7/06 , C12N1/38 , C12N2500/30
Abstract: PURPOSE: A composition for regulating growth of nerve cells containing coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient is provided to be used as a therapeutic agent for treating neurodegenerative diseases such as Alzheimer's diseases or Parkinson's disease without side effects. CONSTITUTION: A composition for regulating growth of nerve cells contains a coprisin peptide derivative, CopA3(9-mer disulfide dimer), with an amino acid sequence. The derivative is a regulator which promotes growth of nerve cells or suppresses programmed cell death of nerve cells. The nerve cells are brain cells. The derivative is D-type and is derived from an insect. The derivative is used for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease.
Abstract translation: 目的：提供用于调节神经细胞生长的组合物，该组合物作为活性成分用作治疗神经变性疾病如阿尔茨海默病或帕金森氏病的治疗剂，CopA3（9-聚体二硫化物二聚体） 效果。 构成：用于调节神经细胞生长的组合物含有具有氨基酸序列的共立克斯肽衍生物CopA3（9-聚体二硫化物二聚体）。 该衍生物是促进神经细胞生长或抑制神经细胞程序性细胞死亡的调节剂。 神经细胞是脑细胞。 衍生物是D型，衍生自昆虫。 该衍生物用于治疗神经变性疾病如阿尔茨海默氏病，帕金森病或亨廷顿舞蹈病。
-
公开(公告)号：KR101029491B1
公开(公告)日：2011-04-18
申请号：KR1020090101244
申请日：2009-10-23
Applicant: 대진대학교 산학협력단
CPC classification number: C12Q3/00 , C07K14/33 , C12Y305/01098
Abstract: PURPOSE: A method for suppressing cytotoxic action of clostridium difficile toxin is provided to suppress deacetylation and to cytotoxic mechanism. CONSTITUTION: A method for suppressing interaction of clostridium difficile toxin in a cell is performed by controlling tubulin-deacetylation of cells. The cells are epithelial cells of large intestine. The suppression method is used for treating Pseudomembranous colitis, Crohn's disease, and Ulcerative colitis.
Abstract translation: 目的：提供一种抑制艰难梭菌毒素的细胞毒作用的方法，以抑制脱乙酰化和细胞毒作用机制。 构成：通过控制细胞的微管蛋白脱乙酰化来进行抑制细菌中艰难梭菌毒素相互作用的方法。 细胞是大肠上皮细胞。 抑制方法用于治疗假膜性结肠炎，克罗恩病和溃疡性结肠炎。
-
-
-
-
-
-
Search Results
7
records
(took 0.018 seconds)
